Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Abbott has received the US Food and Drug Administration (FDA) approval for infant-specific dosage of CREON (pancrelipase) delayed-release capsules for the treatment of exocrine pancreatic insufficiency (EPI) due to cystic fibrosis (CF).
Subscribe to our email newsletter
CREON delayed-release capsules (pancreatic enzyme medicine) are indicated for the improving food digestion in people who cannot digest food properly because they have EPI.
Abbott Global Pharmaceutical Development vice president Eugene Sun said they know that the need for consistent, precise dosing of pancreatic enzyme replacement therapy is critical for infants and children living with cystic fibrosis.
"This approval means that CREON will now be available in four dosing options, including both the lowest and highest dosage strengths available to patients in the US, providing improved dosing titration options and flexibility into adulthood," Sun said.